[Form 4] PROVECTUS BIOPHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.

Insights

Financial Analyst

TL;DR: CEO converted a $100,000 promissory note into preferred stock that represents 377,600 common shares; ownership now 2,418,447 shares.

The transaction replaced an 8% unsecured debt obligation with equity via conversion into Series D-1 Preferred Stock at a $2.862 conversion price, then into an equity-equivalent of 377,600 common shares. This reduces on-balance-sheet debt from this instrument and increases potential common share count if conversion occurs. The filing documents the mechanical conversion and the reporting person's post-transaction beneficial ownership; no cash proceeds or additional terms beyond conversion mechanics are disclosed in the filing.

Corporate Governance Expert

TL;DR: Insider (CEO/Director) executed a standard conversion of a convertible note into preferred stock, recorded per Section 16 reporting rules.

The Form 4 discloses a single insider transaction converting the 2024 Note into Series D-1 Preferred Stock and the related common share equivalence. The filing clarifies automatic conversion timing (June 20, 2026) and conversion ratio (1 preferred to 10 common). This is a disclosure of ownership change rather than a new issuance event; it provides transparency on insider holdings and potential future voting/dilution outcomes tied to the preferreds conversion schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	09/19/2025		M			$100,000	09/19/2024	09/19/2025	Series D-1 Convertible Preferred Stock(3)(4)	37,760	$0	$1,225,000	D
Series D-1 Convertible Preferred Stock	(1)	09/19/2025		M		37,760		09/19/2025	(2)	Common Stock	377,600	$0	2,418,447	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.

4. On September 19, 2025, the 2024 Note was converted into 37,760 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.